[Therapeutic effect of anti-HMGB1 antibody and anti-RAGE antibody on SIRS/sepsis].
High mobility group box-1 (HMGB1) is intranuclear architectural protein. Once HMGB1 released to extracellular, it has been implicated to act as a novel proinflammatory cytokine, called "Late mediator", in SIRS/sepsis. This danger signal transmits through receptor for advanced glycation end-products (RAGE). In this study, we hypothesized whether treatment of anti-HMGB1 or anti-RAGE antibody would block LPS-lethality in septic mice. We measured survival rate of septic mice with or without antibodies, resulting in significant improvement with antibodies-treated mice. LPS-induced acute lung injury was almost disappeared by antibody treatment, because these antibodies were inhibited HMGB1 and RAGE expression in lung. Treatment of anti-HMGB1 or anti-RAGE antibody seems to be valid therapy against SIRS/sepsis.
Unoshima
Masako
M
Anesthesiology, Department of Brain and Nerve Science, Oita University, Faculty of Medicine.
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D024742:HMG-Box Domains / Q000276:immunology*; D051379:Mice; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000276:immunology*; D018805:Sepsis / Q000628:therapy*; D018746:Systemic Inflammatory Response Syndrome / Q000628:therapy
D000906:Antibodies; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic